EMPE Diagnostics poised to substantially impact global fight against TB

EMPE Diagnostics, a renowned biotechnology company headquartered in Sweden, is revolutionising the field of infectious disease diagnostics, particularly concerning tuberculosis (TB).

With a strong emphasis on TB detection, EMPE is making its mark in India by introducing the mfloDxTM MDR-TB diagnostic tool, which has been recognised by the World Health Organisation (WHO). The company's overarching vision is to enhance India's efforts in combating tuberculosis while simultaneously fostering local job opportunities and contributing to the growth of the country's economy. To achieve this, EMPE has established its first Global Production and Sales Unit in Hyderabad, enabling the company to meet the global demand for TB diagnostic kits. Furthermore, these diagnostic kits are currently undergoing clinical evaluation in multiple countries.

EMPE's primary goal is to provide user-friendly diagnostic tests that deliver conclusive results for TB patients. By doing so, the company aims to reduce the life-threatening complications and consequences associated with the disease, particularly in countries heavily burdened by TB. The TB diagnostic kit developed by EMPE is affordable, easily interpretable, customisable, and well-suited for clinical laboratories with limited resources. Importantly, this kit can deliver results within three hours, without requiring advanced instruments.

Aligned with the WHO's recommendations for rapid molecular testing in first-line diagnostic monitoring for suspected TB cases worldwide, EMPE's innovative mfloDxTM MDR-TB diagnostic kit offers a groundbreaking solution. It allows for the detection of Mycobacterium tuberculosis and provides insights into its genotypic resistance profile through visual signals. Clinicians can obtain confirmatory results within just three hours, presented in a simple ‘YES’ or ‘NO’ format. This expedited diagnosis enables prompt and effective antibiotic treatment, effectively curbing the transmission of drug-resistant strains of TB.

In countries with a high burden of TB, clinicians often face the challenge of initiating antibiotic treatment without proper diagnosis. This is primarily due to the scarcity or absence of user-friendly diagnostic tests that can deliver definitive results. Consequently, patients receive suboptimal therapy with ineffective drugs, leading not only to treatment failure but also facilitating the spread of drug-resistant TB within society. This, in turn, increases the risk of developing more resistant and difficult-to-treat forms of the disease. Recognising this critical issue, the WHO strongly advocates for rapid molecular testing in first-line diagnostic monitoring for all suspected TB cases worldwide. EMPE's diagnostic test kits play a crucial role in significantly reducing the time required to initiate effective therapy for TB patients, starting from the initial contact between the patient and the healthcare facility.

With its cutting-edge technology and commitment to improving TB diagnostics, EMPE Diagnostics is poised to substantially impact the global fight against tuberculosis. By providing affordable, user-friendly, and rapid diagnostic solutions, EMPE aims to save lives, prevent the spread of drug resistance, and contribute to the overall goal of eradicating TB as a public health threat.